152 related articles for article (PubMed ID: 34650930)
1. Bevacizumab Combined with Corticosteroids Does Not Improve the Clinical Outcome of Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis.
Li H; Rong X; Hu W; Yang Y; Lei M; Wen W; Yue Z; Huang X; Chua MLK; Li Y; Cai J; He L; Pan D; Cheng J; Pi Y; Xue R; Xu Y; Tang Y
Front Oncol; 2021; 11():746941. PubMed ID: 34650930
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab Monotherapy Reduces Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma Patients: A Randomized Controlled Trial.
Xu Y; Rong X; Hu W; Huang X; Li Y; Zheng D; Cai Z; Zuo Z; Tang Y
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1087-1095. PubMed ID: 29885994
[TBL] [Abstract][Full Text] [Related]
3. Clinical Variables for Prediction of the Therapeutic Effects of Bevacizumab Monotherapy in Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis.
Li Y; Huang X; Jiang J; Hu W; Hu J; Cai J; Rong X; Cheng J; Xu Y; Wu R; Luo J; Tang Y
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):621-629. PubMed ID: 29413276
[TBL] [Abstract][Full Text] [Related]
4. Blood-Brain Barrier Repair of Bevacizumab and Corticosteroid as Prediction of Clinical Improvement and Relapse Risk in Radiation-Induced Brain Necrosis: A Retrospective Observational Study.
Xue R; Chen M; Cai J; Deng Z; Pan D; Liu X; Li Y; Rong X; Li H; Xu Y; Shen Q; Tang Y
Front Oncol; 2021; 11():720417. PubMed ID: 34692494
[TBL] [Abstract][Full Text] [Related]
5. Mortality of early treatment for radiation-induced brain necrosis in head and neck cancer survivors: A multicentre, retrospective, registry-based cohort study.
Pan D; Rong X; Chen D; Jiang J; Ng WT; Mai H; Li Y; Li H; Cai J; Cheng J; Xu Y; Chua MLK; Simone CB; Lattanzi S; Tang Y
EClinicalMedicine; 2022 Oct; 52():101618. PubMed ID: 36034411
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab as a treatment for radiation necrosis following stereotactic radiosurgery for brain metastases: clinical and radiation dosimetric impacts.
Li J; He J; Cai L; Lai M; Hu Q; Ren C; Wen L; Wang J; Zhou J; Zhou Z; Li S; Ye M; Shan C; Chen L; Zhou C
Ann Palliat Med; 2021 Feb; 10(2):2018-2026. PubMed ID: 33549015
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.
Khan M; Zhao Z; Arooj S; Liao G
BMC Cancer; 2021 Feb; 21(1):167. PubMed ID: 33593308
[TBL] [Abstract][Full Text] [Related]
8. The correlation between serum apolipoprotein B/apolipoprotein A1 ratio and brain necrosis in patients underwent radiotherapy for nasopharyngeal carcinoma.
Li H; Zheng D; Xie F; Huang X; Zhuo X; Lin J; Li Y; Tang Y
Brain Behav; 2020 Mar; 10(3):e01554. PubMed ID: 32017458
[TBL] [Abstract][Full Text] [Related]
9. Temporal Cerebral Microbleeds Are Associated With Radiation Necrosis and Cognitive Dysfunction in Patients Treated for Nasopharyngeal Carcinoma.
Shen Q; Lin F; Rong X; Yang W; Li Y; Cai Z; Xu P; Xu Y; Tang Y
Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1113-20. PubMed ID: 27026315
[TBL] [Abstract][Full Text] [Related]
10. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
11. Comparison between high-dose and low-dose intravenous methylprednisolone therapy in patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma.
Zhuo X; Huang X; Yan M; Li H; Li Y; Rong X; Lin J; Cai J; Xie F; Xu Y; Chen K; Tang Y
Radiother Oncol; 2019 Aug; 137():16-23. PubMed ID: 31048233
[TBL] [Abstract][Full Text] [Related]
12. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.
Lee NY; Zhang Q; Pfister DG; Kim J; Garden AS; Mechalakos J; Hu K; Le QT; Colevas AD; Glisson BS; Chan AT; Ang KK
Lancet Oncol; 2012 Feb; 13(2):172-80. PubMed ID: 22178121
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab is an effective treatment for symptomatic cerebral necrosis after carbon ion therapy for recurrent intracranial malignant tumours: A case report.
Liu R; Luo H; Zhang Q; Sun S; Liu Z; Wang X; Geng Y; Zhao X
Mol Clin Oncol; 2022 Jul; 17(1):114. PubMed ID: 35747599
[TBL] [Abstract][Full Text] [Related]
14. Treatment of cerebral radiation necrosis with bevacizumab: the Cleveland clinic experience.
Sadraei NH; Dahiya S; Chao ST; Murphy ES; Osei-Boateng K; Xie H; Suh JH; Peereboom DM; Stevens GH; Ahluwalia MS
Am J Clin Oncol; 2015 Jun; 38(3):304-10. PubMed ID: 23799286
[TBL] [Abstract][Full Text] [Related]
15. Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain.
Dashti SR; Spalding A; Kadner RJ; Yao T; Kumar A; Sun DA; LaRocca R
J Neurosurg Pediatr; 2015 Jan; 15(1):20-5. PubMed ID: 25360851
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery.
Boothe D; Young R; Yamada Y; Prager A; Chan T; Beal K
Neuro Oncol; 2013 Sep; 15(9):1257-63. PubMed ID: 23814264
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review.
Liao G; Khan M; Zhao Z; Arooj S; Yan M; Li X
Front Oncol; 2021; 11():593449. PubMed ID: 33842309
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases.
Glitza IC; Guha-Thakurta N; D'Souza NM; Amaria RN; McGovern SL; Rao G; Li J
Melanoma Res; 2017 Dec; 27(6):580-584. PubMed ID: 28817446
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Kawashima Y; Fukuhara T; Saito H; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Seike M; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Respir Med; 2022 Jan; 10(1):72-82. PubMed ID: 34454653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
